Lithium Dosing Study
A legfontosabb adatok
- Ki végzi
- Massachusetts General Hospital
- Hol
- Boston (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 250 fő, tervezett
- Kezdés
- 2026. nov. 16.
- Várható befejezés
- 2027. nov. 1.
- A vizsgálat típusa
- Beavatkozással járó, 5 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Lithium Orotate (LiO)
- Placebo
- A regiszteradat frissítve
- 2026. november 16.
Ki vehet részt
- Életkor
- 60 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 34 feltétel megnézéseKevesebb
Ki vehet részt
- Age 60 years or older at study entry Self-reported ability to read and understand English. As all study surveys have been validated in English, we will limit participation to potential subjects able to read English
- Able to provide informed consent
- Must meet criteria for one of the three following cognitive statuses:
- Cognitively normal/unimpaired, (TICS-41 score ≥34 with presence of subjective cognitive concerns and without significant hearing impairment
- For those without hearing impairment, TICS-41 score 23 to <34 (mild objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of MCI
- For those without hearing impairment, TICS-41 score >15 to <23 (moderate objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of mild-stage AD dementia
- Must be able and willing to adhere to study procedures
- Participants with moderate objective impairment or clinician diagnosis of AD dementia must have a study partner willing to participate in the study with them
Ki nem vehet részt
- Concurrent use of anti-amyloid therapies (e.g., Donanemab, Lecanemab)
- Concurrent participant in an ongoing clinical trial involving taking a study drug or supplement
- History of lithium toxicity, intolerance or hypersensitivity
- History of diagnosed kidney disorders (e.g., chronic kidney disease, dialysis or renal transplant, acute kidney injury within past 6 months)
- Unstable thyroid disorders (e.g., medication change in the last 90 days) or history of thyroid surgery, radioactive iodine treatment or active thyroiditis in the last 90 days
- Self-reported major psychiatric and neurological disorders
- Bipolar disorder, schizophrenia, or unstable major depression (e.g., recent hospitalization, medication change in the last 90 days)
- To optimize participant safety and to ensure that individuals with any degree of suicidal ideation at baseline are not included in the study, the presence of any suicidal ideation at screening will be defined as a score of >0 on PHQ-9 Item 9 or as spontaneously reported during screening. The PHQ-9 will also be administered at 6- and 12-week follow-up time points as a safety monitoring measure. A score of 1 or greater on PHQ-9 Item 9, or spontaneous report of current suicidal ideation at any point during the study, will trigger the suicidality and psychiatric safety procedures detailed under 'Monitoring and Quality Assurance'
- Parkinson disease or other non-AD neurodegenerative disorders (e.g., Huntington's disease)
- Self-reported medical conditions
- Diagnosis of cardiovascular disease or major cardiovascular procedures in the last 6 months (e.g., cardiac conduction abnormalities, heart attack, stroke, transient ischemic attack, angina pectoris, coronary-artery bypass grafting, percutaneous coronary intervention, cardioversion or ablation)
- Diagnosis or treatment of cancer (except non-melanoma skin cancer) in the last 6 months
- History of liver disease
- Score of >50% likelihood of significant hearing impairment according to the Hearing Handicap Inventory-Screening Version (HHIE-S)
- Any other serious illness or condition that, in the opinion of the investigators, would preclude safe participation or completion of the study procedures
- Those with hearing impairment who do not report a clinician diagnosis of MCI or AD dementia given concerns for lack of awareness of objective memory decline which could lead to incorrect categorization without use of the TICS-41
- Failure to complete the baseline blood collection
- Lab values within the abnormal range (adjusted for age and sex where relevant) for renal function, reflex thyroid tests, and liver function
- Lithium-specific exclusions
- Use of any lithium formulation in the last six months
- Unwilling to forego use of any non-study lithium formulation during the trial
- Other exclusions
- TICS-41 score ≤15
- Those who report "severe" for items 21-29 on the LiSERS questionnaire
- UBACC (the University of California, San Diego Brief Assessment of Capacity to Consent) < 11 indicating inability to provide informed consent. The clinical research coordinator will conduct a comprehension check of the consent form using the UBACC, which will require a perfect score of 11 out of 11 points to indicate capacity to provide informed consent. Prospective participants will be allowed two tries of the UBACC to achieve a score of 11
- Must reside in the states of Connecticut, Rhode Island, Massachusetts, Maine, New Hampshire, or Vermont and be able to have blood draws completed at a New England Quest location in those states
Helyszínek itt: Egyesült Államok
- Massachusetts General HospitalBoston, Egyesült ÁllamokContact: Olivia I Okereke, MDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
LiDS is a dosing study to evaluate the safety, tolerability, and feasibility of daily oral Lithium Orotate (LiO) in aging adults at increased risk for progression of cognitive problems, including Alzheimer's disease and related dementias.
A vizsgálat 5 csoportja
- PlaceboPlacebo, összehasonlításként
Placebo pill taken daily for the 12 week study participation period. Placebo pills are in packaging identical to the LiO groups.
- 0.5 mg/dayMár használt kezelés, összehasonlításként
0.5 mg/day of LiO pills for the 12 week study participation period.
Kezelés: Lithium Orotate (LiO)
- 1.0 mg/dayMár használt kezelés, összehasonlításként
1.0 mg/day of LiO pills for the 12 week study participation period.
Kezelés: Lithium Orotate (LiO)
- 2.5 mg/dayMár használt kezelés, összehasonlításként
2.5 mg/day of LiO pills for the 12 week study participation period.
Kezelés: Lithium Orotate (LiO)
- 5.0 mg/dayMár használt kezelés, összehasonlításként
5.0 mg/day of LiO pills for the 12 week study participation period.
Kezelés: Lithium Orotate (LiO)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Dosing Study of Lithium Orotate for Safety, Tolerability, and Feasibility for Early Stages of Alzheimer's Disease and Related Dementias
- A regiszteradat frissítve
- 2026. november 16.